Peter Langmuir, MD
Advertisement
Articles by Peter Langmuir, MD
eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.
Advertisement
Latest Updated Articles
Dr. Langmuir Discusses Vandetanib Clinical TrialsPublished: March 15th 2011 | Updated:
Dr. Langmuir Explains the Side Effects of VandetanibPublished: April 7th 2011 | Updated:
Vandetanib Advantages in Medullary Thyroid CancerPublished: March 15th 2011 | Updated:
Dr. Langmuir on Vandetanib in Medullary Thyroid CancerPublished: March 15th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5